266 related articles for article (PubMed ID: 23604531)
1. A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer.
Agelaki S; Kontopodis E; Kotsakis A; Chandrinos V; Bompolaki I; Zafeiriou Z; Papadimitraki E; Stoltidis D; Kalbakis K; Georgoulias V
Cancer Chemother Pharmacol; 2013 Jul; 72(1):45-51. PubMed ID: 23604531
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancer.
Spigel DR; Greco FA; Burris HA; Shipley DL; Clark BL; Whorf RC; Arrowsmith ER; Hainsworth JD
Clin Lung Cancer; 2011 May; 12(3):187-91. PubMed ID: 21663862
[TBL] [Abstract][Full Text] [Related]
3. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
[TBL] [Abstract][Full Text] [Related]
4. Myelotoxicity of oral topotecan in relation to treatment duration and dosage: a phase I study.
Stathopoulos GP; Ardavanis A; Papakotoulas P; Pectasides D; Papadopoulos G; Antoniou D; Athanasiadis A; Trafalis D; Anagnostopoulos A; Koutantos J; Vaslamatzis M
Anticancer Drugs; 2010 Feb; 21(2):202-5. PubMed ID: 20010424
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of weekly doxorubicin and oral topotecan for patients with relapsed or refractory small cell lung cancer (SCLC): A Fred and Pamela Buffet Cancer Center Clinical Trials Network study.
Ernani V; Jahan R; Smith LM; Marr AS; Kimbrough SE; Kos ME; Tijerina J; Pivovar S; Lakshmanan I; Ketcham M; Rauth S; Mallya K; Nasser MW; Jain M; Kessinger A; Batra SK; Ganti AK
Cancer Treat Res Commun; 2020; 22():100162. PubMed ID: 31675535
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
Miller AA; Al Omari A; Murry DJ; Case D
Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of oral topotecan in advanced non-small cell lung cancer.
White SC; Cheeseman S; Thatcher N; Anderson H; Carrington B; Hearn S; Ross G; Ranson M
Clin Cancer Res; 2000 Mar; 6(3):868-73. PubMed ID: 10741709
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacologic study of weekly bolus topotecan for advanced non-small-cell lung cancer.
Masuda N; Matsui K; Negoro S; Takeda K; Kudoh S; Nakagawa K; Mukaiyama A; Arase H; Yoshida P; Ijima T; Takada M; Fukuoka M
Clin Lung Cancer; 2010 Jul; 11(4):271-9. PubMed ID: 20630830
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
Pentheroudakis G; Briasoulis E; Karavassilis V; Mauri D; Tzamakou E; Rammou D; Pavlidis N
Chemotherapy; 2005 May; 51(2-3):154-61. PubMed ID: 15886476
[TBL] [Abstract][Full Text] [Related]
10. A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients.
Homesley HD; Hall DJ; Martin DA; Lewandowski GS; Vaccarello L; Nahhas WA; Suggs CL; Penley RG
Gynecol Oncol; 2001 Nov; 83(2):394-9. PubMed ID: 11606103
[TBL] [Abstract][Full Text] [Related]
11. A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer.
Shah C; Ready N; Perry M; Kirshner J; Gajra A; Neuman N; Garziano S
Lung Cancer; 2007 Jul; 57(1):84-8. PubMed ID: 17399850
[TBL] [Abstract][Full Text] [Related]
12. A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors.
Kakolyris S; Kouroussis C; Souglakos J; Mavroudis D; Agelaki S; Kalbakis K; Androulakis N; Vardakis N; Vamvakas L; Georgoulias V
Oncology; 2001; 61(4):265-70. PubMed ID: 11721172
[TBL] [Abstract][Full Text] [Related]
13. A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer.
Shibayama T; Hotta K; Takigawa N; Tada A; Ueoka H; Harita S; Kiura K; Tabata M; Segawa Y; Nogami N; Kuyama S; Shinkai T; Tanimoto M
Lung Cancer; 2006 Aug; 53(2):189-95. PubMed ID: 16806573
[TBL] [Abstract][Full Text] [Related]
14. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy.
Jotte R; Conkling P; Reynolds C; Galsky MD; Klein L; Fitzgibbons JF; McNally R; Renschler MF; Oliver JW
J Clin Oncol; 2011 Jan; 29(3):287-93. PubMed ID: 21135284
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer.
Lu C; Komaki R; Lee JS; Shin DM; Palmer JL; Coldman BJ; Pisters KM; Kurie JM; Fossella FV; Glisson BS
Clin Cancer Res; 2003 Jun; 9(6):2085-91. PubMed ID: 12796372
[TBL] [Abstract][Full Text] [Related]
17. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.
O'Brien ME; Ciuleanu TE; Tsekov H; Shparyk Y; Cuceviá B; Juhasz G; Thatcher N; Ross GA; Dane GC; Crofts T
J Clin Oncol; 2006 Dec; 24(34):5441-7. PubMed ID: 17135646
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II study.
Spigel DR; Waterhouse DM; Lane S; Legenne P; Bhatt K
Clin Lung Cancer; 2013 Jul; 14(4):356-63. PubMed ID: 23391616
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum.
Brown JV; Peters WA; Rettenmaier MA; Karlan BY; Dillman RA; Smith MR; Drescher CW; Micha JP
Gynecol Oncol; 2000 Dec; 79(3):495-8. PubMed ID: 11104627
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
